Influence of Gemcitabine Treatment on Immunological and Serological Profile in Patients With Pancreatic Cancer (GEMSTHER)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2009 by Blood Transfusion Centre of Slovenia.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
University Medical Centre Ljubljana
Information provided by:
Blood Transfusion Centre of Slovenia
ClinicalTrials.gov Identifier:
NCT00947102
First received: July 24, 2009
Last updated: January 12, 2010
Last verified: July 2009
  Purpose

Observational study of influence of gemcitabine treatment on serological and immunological status and gene expression profile in patients with pancreatic tubular carcinoma after tumor resection.


Condition Intervention
Pancreatic Tubular Adenocarcinoma
Other: Observation

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Observational Study - Influence of Gemcitabine Treatment on Immunological and Serological Profile in Patients With Pancreatic Tubular Carcinoma

Resource links provided by NLM:


Further study details as provided by Blood Transfusion Centre of Slovenia:

Study Start Date: February 2009
Estimated Study Completion Date: December 2011
Estimated Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Pancreatic tubular adenocarcinoma
Patients with pancreatic tubular adenocarcinoma
Other: Observation

  Eligibility

Ages Eligible for Study:   30 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients after resection of pancreatic tubular adenocarcinoma

Criteria

Inclusion Criteria:

  • ECOG performance status 0-2 at the time of inclusion
  • Following R0 or R1 pancreatic tubular adenocarcinoma resection

Exclusion Criteria:

  • Pregnancy
  • Serious comorbidity
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00947102

Contacts
Contact: Borut Stabuc, MD, PhD +386 1 522 22 10 borut.stabuc@kclj.si
Contact: Lojze Smid, MD lojze.smid.jr@mf.uni-lj.si

Locations
Slovenia
University Medical Centre Ljubljana; Department for Gastroenterology Recruiting
Ljubljana, Slovenia, 1000
Contact: Borut Stabuc, MD, PhD    +386 1 522 2210    borut.stabuc@kclj.si   
Contact: Lojze Smid, MD       lojze.smid.jr@mf.uni-lj.si   
Principal Investigator: Borut Stabuc, MD, PhD         
Sponsors and Collaborators
Blood Transfusion Centre of Slovenia
University Medical Centre Ljubljana
  More Information

No publications provided

Responsible Party: Primoz Rozman MD, PhD, Blood Transfusion Centre of Ljubljana
ClinicalTrials.gov Identifier: NCT00947102     History of Changes
Other Study ID Numbers: Gemcitabine1
Study First Received: July 24, 2009
Last Updated: January 12, 2010
Health Authority: Slovenia: Ethics Committee

Keywords provided by Blood Transfusion Centre of Slovenia:
pancreatic tubular adenocarcinoma
gemcitabine
gene expression
immunological status
serological status
pancreatic tubular adenocarcinoma adjuvant setting

Additional relevant MeSH terms:
Adenocarcinoma
Carcinoma
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Gemcitabine
Anti-Infective Agents
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antiviral Agents
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Radiation-Sensitizing Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on October 29, 2014